Ambroxol hydrochloride increases glucosylceramidase activity in control, Gaucher disease and Parkinson’s disease with GBA mutation cell lines, by activating components of the CLEAR network through TFEB combined with chaperone activity (Supplementary Fig. 2). Here, TFEB is linked to Parkinson disease.